Treat the Cow, Not the Crowd

Cattle health researchers are asking a simple question with expensive consequences: does every animal in the group really need the same antibiotic treatment?

Treat the risk: Brad White, professor of production medicine and director of the Beef Cattle Institute at Kansas State University, helped develop models designed to identify cattle groups most likely to benefit economically from metaphylaxis, the preventive treatment of a group when bovine respiratory disease risk is high. In a dataset covering more than 2.2 million cattle, 72% of cohorts that had not received metaphylaxis would not have benefited economically from adding it.

Read the pen: Entry weight, sex, group size and performance were among the factors tied to whether treatment penciled out. The goal is not to eliminate antibiotics. It is to use them where animal-health risk justifies the cost, rather than treating every pen as if the risk were identical.

Gut check: A separate project led by Dale Woerner, Cargill Endowed Professor in Sustainable Meat Science at Texas Tech University, found liver abscesses in beef-on-dairy cattle were associated more closely with rumen changes than inherited traits. That points researchers toward management and earlier detection instead of simply breeding around the problem. Liver abscesses cost the U.S. beef industry an estimated $256 million annually.

Why it matters: Better targeting could protect cattle health, trim treatment costs and preserve antibiotic effectiveness. In other words, the future may be less “treat the crowd” and more herd the data.